Harriet Kluger, MD

Professor of Medicine (Medical Oncology); Associate Director, Hematology/Oncology Fellowship Program; Associate Cancer Center Director for Education and Training

Physician Biography


Dr. Kluger is a medical oncologist who sees patients with melanoma and renal cell carcinoma. Her research interests focus on developing new drugs and biomarkers predictive of response to these drugs in melanoma and renal cell carcinoma. She participates in a number of clinical trials studying new agents for the treatment of these diseases, both targeting the immune system and the cancer cell. She runs and active research laboratory that studies tumors and cells from patients treated with novel therapies.

Clinical Interests

  • Medical Oncology
  • Melanoma

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Medical Oncology: Subset Medical Oncology Faculty

General Adult Urology

Urologic Oncology Program

Yale Cancer Center: Melanoma Program | Prostate & Urologic Cancers Program

Yale Medicine

Office of Cooperative Research

Board Certifications

  • Medical Oncology AB of Internal Medicine (2002)

Clinical Trials

Conditions Study Title
Kidney A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti−PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy
Kidney, Melanoma, skin A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-214 and Nivolumab in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies
Lung, Melanoma, skin Phase I Study of MK-3475 (Pembrolizumab) in Patients With Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
Kidney, Melanoma, skin A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
Melanoma, skin A Phase 1b/2 Open-label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies
Kidney, Melanoma, skin A Phase I Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Solid Tumors
Melanoma, skin A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Brain and Nervous System, Lung, Melanoma, skin A Phase II Trial of Pembrolizumab Plus Bevacizumab in Patients With Metastatic Melanoma or Non-small Cell Lung Cancer With Untreated Brain Metastases
Kidney, Melanoma, skin A Phase I/II, Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-214 in Subjects with Locally Advanced or Metastatic Solid Tumor Malignancies
Melanoma, skin A Phase II, Multicenter, Single-arm Study to Assess the Safety, Feasibility, and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-144) Followed by IL-2 for Treatment of Metastatic Melanoma
Lung, Melanoma, skin MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
Other Skin A Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC)
Lung, Melanoma, skin Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC
Kidney Active Surveillance of the Small Renal Mass
Melanoma, skin A Phase I, Open Label, Dose Escalation Study of MGA271 (Fc-optimized Humanized Anti-B7-H3-Expressing Neoplasms or Neoplasms Whose Vasculature Expresses B7-H3)
Melanoma, skin A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

Edit this profile

Contact Info

Harriet Kluger, MD
Patient Care Location
Yale Cancer CenterYale New Haven Hospital
20 York Street, Ste North Pavilion 4

New Haven, CT 06510
View on map...
Mailing Address
PO Box 208032
New Haven, CT 06520-8028